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MaOBJECTIVES The aim of this study was to explore the relationship between temporal changes in coronary plaque
volume and the intensity of lipid-lowering treatments, utilizing coronary computed tomography angiography (CTA).
BACKGROUND Coronary CTA has acceptable accuracy in terms of quantitative measurement of plaque volume.
Although, coronary CTA is perhaps capable of identifying the differences in plaque volume progression according to the
intensity of lipid lowering treatment, to date, few studies have examined this notion.
METHODS In this multicenter, observational study, the authors reviewed 467 patients who underwent serial coronary
CTA with a scan period of more than 2 years (median 3.2 years [2.4 to 4.8]) apart, and whose laboratory data were
available within 1 month of both the baseline and follow-up coronary CTA. Among them, 147 patients (comprising 336
vessels) with visible plaque were enrolled in this study. The authors performed quantitative assessment of coronary
plaque in both. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) with a cut off value below 70 mg/dl
at follow-up were compared with those who did not.
RESULTS Patients with LDL-C below 70 mg/dl displayed a signiﬁcant attenuation in plaque progression as compared
with those with follow-up LDL-C levels $70 mg/dl (12.7  38.2 mm3 vs. 44.2  73.6 mm3, respectively; p ¼ 0.014). In
multivariate analysis, factors inﬂuencing plaque progression per year was follow-up LDL-C levels $70 mg/dl (beta 0.193;
p ¼ 0.021).
CONCLUSIONS Strict LDL-C control appeared to signiﬁcantly attenuate plaque volume progression based
on noninvasive quantitative assessment by coronary CTA. (J Am Coll Cardiol Img 2017;10:437–46)
© 2017 by the American College of Cardiology Foundation.m the aDivision of Cardiology, Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea;
ivision of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health
stem, Seoul, South Korea; cDivision of Cardiology, Department of Internal Medicine, Myungji Hospital, Goyang-si, Gyeonggi-
, South Korea; dMayo Clinic, Division of Cardiology, Department of Internal Medicine, Scottsdale, Arizona; eWeill Cornell
dical College and the New York-Presbyterian Hospital, New York, New York; fDivision of Cardiology, Seoul National
iversity Hospital, Seoul, South Korea; gDivision of Cardiology, Gangnam Severance Hospital, Seoul, South Korea; and the
ivision of Cardiology, Busan Medical Center, Busan, South Korea. This work was supported by the ICT R&D program of
IP/IITP [10044910, Development of Multi-modality Imaging and 3D Simulation-Based Integrative Diagnosis-Treatment
pport Software System for Cardiovascular Diseases]. Dr. Min has received funding from the National Institutes of Health/
tional Heart, Lung, and Blood Institute (NIH/NIHLBI) grants R01HL111141, R01HL115150, R01HL118019, and U01HL105907,
d Qatar National Research Foundation grant NPRP09-370-3-089; is a consultant for HeartFlow; is on the scientiﬁc advisory
ard of Arineta; has ownership of MDDX and Autoplaq; and has a research agreement with GE Healthcare. All other authors
ve reported that they have no relationships relevant to the contents of this paper to disclose. Prediman K. Shah, MD, served
the Guest Editor for this paper.
nuscript received February 19, 2016; revised manuscript received April 1, 2016, accepted April 18, 2016.
ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
CAD = coronary artery disease
CTA = computed tomography
angiography
ECG = electrocardiogram
HDL-C = high-density
lipoprotein cholesterol
IVUS = intravascular
ultrasound
LDL-C = low-density
lipoprotein-cholesterol
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438C oronary atherosclerosis is a majorcause of morbidity and mortality,carrying a global burden of 17 million
deaths annually (1). Low-density lipoprotein
cholesterol (LDL-C) has been demonstrated
to play an essential role in the progression
of atherosclerotic coronary artery disease
(CAD). Prior clinical trials have demonstrated
a salutary effect of lowering LDL-C with sta-
tins (2,3), whereby intensive LDL-C lowering
was found to be associated with improved
event-free survival (4). Early studies docu-
mented that lowering LDL-C levels reducesthe progression of CAD observed via serial coronary
angiography (5). Further still, the precise quantiﬁca-
tion of atheroma volume using intravascular ultra-
sound (IVUS) has shown that intensive lowering of
LDL-C levels can halt the progression of CAD (6), or
even promote atherosclerotic regression (7).SEE PAGE 447Serial assessment of coronary plaques using
coronary angiography or IVUS has contributed to the
understanding of the natural history and pathophys-
iology of CAD, and is therefore considered a surrogate
endpoint for evaluating novel cardiovascular thera-
peutics (8–10). Nevertheless, these methods are
invasive, expensive, and can be associated with sig-
niﬁcant adverse complications, making them unsuit-
able for routine clinical use. In addition, most
available studies relative to invasive imaging tech-
niques have typically included fewer numbers of pa-
tients with a generally shorter-term follow-up. Recent
improvements in coronary computed tomography
angiography (coronary CTA) technology have allowed
for the noninvasive assessment of CAD with high
diagnostic performance compared with invasive
measures (11,12). In light of this, coronary CTA has
emerged as a potential alternative to invasive angi-
ography in many circumstances, including (but not
conﬁned to) stenosis grading and plaque quantiﬁca-
tion (13–15). Although a small number of serial coro-
nary CTA studies have been published (16–18), most
prior analyses were limited to a small study sample or
a speciﬁc subset of lesions. Thus, in the present study,
our objective was to examine changes in coronary
atherosclerosis along the full length of the coronary
vascular tree using coronary CTA, as well as to assess
the serial changes in coronary plaque volume occur-
ring as a result of intensive lowering of LDL-C levels.
METHODS
PATIENT SELECTION. In this multicenter, obser-
vational study, we enrolled 467 consecutiveparticipants who underwent serial coronary CTA us-
ing 64-slice multidetector computed tomography and
whose laboratory data were available within 1 month
of both the baseline and follow-up evaluations at 4
centers in Korea consisting of Severance Cardiovas-
cular Hospital, Seoul National University Hospital,
Gangnam Severance Hospital, and Busan Medical
Center. Patients with plaque-free coronary arteries
(n ¼ 153), a history of coronary bypass surgery
(n ¼ 108), or inadequate imaging quality for analy-
sis (n ¼ 59) were excluded. Normal, plaque-free
coronary arteries (n ¼ 76), stent-implanted vessels
(n ¼ 17), or vessels with poor imaging quality due to
artifacts (n ¼ 12) were excluded from the per-vessel
analysis. In total, 147 patients (comprising 336 ves-
sels) with plaque visible using coronary CTA were
enrolled in this study (Figure 1). The period between
coronary CTA scans was at least 24 months. Patients
were referred for coronary CTA for a variety of in-
dications, including general health evaluation, eval-
uation of symptoms, and signs of cardiac disease
(Table 1). The appropriate institutional review board
committee approved this study.
CORONARY CTA PROTOCOL. Patients with pre-
multidetector computed tomography heart rates >65
beats/min received a single oral dose (50 mg) of
metoprolol tartrate (Betaloc, Yuhan, Seoul, Korea), 1
to 2 h before their CT examination unless b-adren-
ergic blocking agents were contraindicated (overt
heart failure or atrioventricular conduction abnor-
malities). Patients were scanned using a 64-slice CT
scanner in various centers. Coronary CTA was per-
formed using prospective electrocardiogram (ECG)
gating with the following scan parameters: rotation
time 330 ms; slice collimation 64.0  0.6 mm; tube
voltage 100 to 120 kV; tube current 600 to 800 mA,
depending on patient size; table feed/scan 3.8 mm;
and pitch factor 0.2. ECG-based tube current modu-
lation was applied to 65% of the R-R interval. A real-
time bolus-tracking technique was used to trigger
scan initiation.
Contrast enhancement was achieved with 60 ml
iopamidol (370 mg iodine/ml, Iopamiro, Bracco,
Milan, Italy) injected at 5 ml/s, followed by an injec-
tion of 30 ml of diluted contrast (contrast agent/
saline ¼ 3:7), followed by 30 ml of saline (5 ml/s) using
a power injector (Envision CT, Medrad, Indianola,
Pennsylvania) via an antecubital vein. Axial images
were reconstructed using retrospective ECG gating,
with a slice thickness of 0.75 mm, a slice increment of
0.4 mm, and a medium-to-smooth convolution
kernel. Optimal datasets with the best image quality
were reconstructed, mainly during the mid-to-end
FIGURE 1 A Flowchart Demonstrating Selection of the Study Population
• Observational, multi-center study (four centers in Korea)
• Consecutive participants with serial coronary CTA
• Available laboratory data within one month of both the  
  baseline and follow-up evaluations
(n = 467)
• Three blinded observers analysis CT data
• Quantitative analysis for plaque volume and annual 
   plaque volume change 
Excluded Patients 
• Normal patients (n = 153)
• Bypass surgery (n = 108)
• Inadequate quality (n = 59)
Excluded Vessels
• Plaque free vessel (n = 76)
• Stent implanted vessel (n = 17)
• Inadequate quality (n = 12)
• Serial coronary CTA with plaque
  (n = 147 patients, 336 Vessels)
Among 467 consecutive participants, we excluded patients with plaque-free coronary arteries, a history of coronary bypass surgery, or
inadequate imaging quality for analysis. Furthermore, normal, plaque-free coronary arteries, stent-implanted vessels, or vessels with poor
imaging quality due to artifacts were excluded from the per-vessel analysis. CTA ¼ computed tomography angiography.
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439diastolic phase. The follow-up scan was performed at
least 2 years after the initial CT using the same
protocol.
CORONARY CTA IMAGE ANALYSIS. Datasets (base-
line and follow-up) were transferred to an ofﬂine
workstation for analysis using semiautomated plaque
analysis software (QAngioCT Research Edition v2.0.2,
Medis Medical Imaging Systems, Leiden, the
Netherlands) (19). Three experienced observers (more
than 3 years coronary CTA experience) blinded to theTABLE 1 Causes of Referral for Coronary CTA
Initial Follow-Up
Asymptomatic 83 (56.5) 93 (63.3)
Noncardiac chest pain 12 (8.2) 9 (6.1)
Atypical chest pain 42 (28.6) 33 (22.4)
Typical chest pain 5 (3.4) 8 (5.4)
Shortness of breath 5 (3.4) 4 (2.7)
Values are n (%).
CTA ¼ computed tomography angiography.groups analyzed all the scans and conﬁrmed by Level
III–equivalent cardiologists with experience inter-
preting several thousand coronary CTA scans. The
major vessels (left anterior descending coronary ar-
tery, left circumﬂex coronary artery, and right coro-
nary artery) were considered for analysis using the
modiﬁed 17-segment American Heart Association
model for coronary segment classiﬁcation (20). Le-
sions were matched in baseline and follow-up images
using branch points as landmarks. Deﬁnitions of the
inner lumen and outer vessel areas were performed
semiautomatically, following a stepwise approach.
First, the observer placed an ostial proximal point and
a distal point, and then a centerline originating from
the ostium was automatically extracted. Straight-
ened, multiplanar reformatted images were then
generated, and the lumen and vessel borders were
detected longitudinally by the software in 4 different
cut planes and corrected by the observer. On the basis
of these longitudinal contours, cross-sectional images
at 0.5-mm intervals were calculated to create trans-
versal lumen and vessel wall contours. These were
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440examined, and if necessary, adjusted by the observer.
Gradient magnitude images derived from the coro-
nary CTA images and displaying the degree of CT
density change were used to verify the lumen and
vessel wall borders (Figure 2, Online Figure 1).
MEASUREMENT OF CLINICAL VARIABLES AND
CONFOUNDING VARIABLES. Clinical risk factors,
including hypertension, diabetes mellitus, and
smoking status, were systematically obtained.
Height, body weight, and blood pressure were
measured during the visits. Total cholesterol, tri-
glycerides, high-density lipoprotein cholesterol
(HDL-C), LDL-C, fasting plasma glucose, glycated
hemoglobin, blood urea nitrogen, and serum creati-
nine levels were measured within 1 month of the CT
scan. Diabetes was deﬁned as treatment with oral
hypoglycemic agents or insulin, or fasting
glucose $126 mg/dl. Hypertension was deﬁned as
systolic blood pressure $140 mm Hg and/or diastolic
blood pressure $90 mm Hg, or treatment withFIGURE 2 Representative Imaging for Lumen and Vessel Wall Conto
Example of vessel analysis using semi-automated plaque analysis softwar
Leiden, the Netherlands). After the 3-dimensional centerline was genera
and vessel wall contour detection was performed.antihypertensive agents. Patients were considered to
be active smokers if they currently smoked or had
smoked within the month before the initiation of the
study. Dyslipidemia was deﬁned as total
cholesterol $240 mg/dl, LDL-C $130 mg/dl,
HDL-C #40 mg/dl, triglycerides $150 mg/dl, and/or
treatment with lipid-lowering agents. Laboratory
values for the lipid parameters were obtained within 1
month before coronary CTA examination. The de-
cisions to use statin therapy and the treatment target
of LDL-C were determined by the individual clinician.
STATISTICAL METHODS. Continuous variables are
expressed as median and interquartile range, whereas
categorical variables are presented as absolute values
and proportions. Differences between continuous
variables were analyzed using an independent Stu-
dent t test, whereas differences between categorical
variables were analyzed by the use of a chi-square
test. Changes in lesion characteristics were analyzed
using a Wilcoxon signed rank test. Variables thatur Using Q-angio CT
e (QAngioCT Research Edition v2.0.2, Medis Medical Imaging Systems,
ted from the computed tomography (CT) dataset, automated lumen
TABLE 2 Baseline Patient Characteristics Split Up Based on Follow-Up LDL-C Level
All Patients
(N ¼ 147)
F/U LDL-C
<70 mg/dl
(n ¼ 37)
F/U LDL-C
$70 mg/dl
(n ¼ 110) p Value
Age, yrs 62  8 62  8 62  8 0.982
Male 84 (57.1) 20 (54.1) 64 (58.2) 0.661
BMI, kg/m2 25.1  2.7 24.4  2.4 25.4  2.8 0.079
Hypertension 96 (65.3) 26 (70.3) 70 (63.6) 0.463
Diabetes mellitus 49 (33.3) 20 (54.1) 29 (26.4) 0.002
Active smoking 30 (20.4) 8 (21.6) 22 (21.2) 0.952
Dyslipidemia 42 (27.3) 12 (32.5) 28 (25.5) 0.409
History of PCI 7 (4.8) 3 (8.1) 4 (3.7) 0.269
History of CVA 7 (4.8) 3 (8.1) 4 (3.7) 0.269
NCEP ATP III risk 9.8  7.5 8.5  5.9 10.2  7.9 0.232
Low (<10) 81 (55.1) 21 (56.8) 60 (54.5)
Intermediate (10w20) 47 (32.0) 12 (32.4) 35 (31.8)
High (>20) 19 (12.9) 4 (10.8) 15 (13.6)
Framingham risk 10.3  7.9 9.9  5.8 10.5  8.5 0.694
Low (<10) 92 (62.6) 22 (59.5) 70 (63.6)
Intermediate (10w20) 42 (28.6) 13 (35.1) 29 (26.4)
High (>20) 13 (8.8) 2 (5.4) 11 (10.0)
Number of risk factors 1.64  0.99 1.95  1.08 1.54  0.95 0.029
Values are mean  SD or n (%). The mean interscan period was 3.2  1.1 years.
BMI ¼ body mass index; CVA ¼ cerebrovascular accident; F/U ¼ follow-up; LDL-C ¼ low-density lipoprotein
cholesterol; NCEP ATP III ¼ the National Cholesterol Education Program Adult Treatment Panel III; PCI ¼
percutaneous coronary intervention.
TABLE 3 The Change of Statin Use and Laboratory Test After Index Coronary CTA
All Patients
(N ¼ 147)
F/U LDL-C
<70 mg/dl
(n ¼ 37)
F/U LDL-C
$70 mg/dl
(n ¼ 110) p Value
Statin use before index coronary CTA 57 (38.8) 21 (56.8) 36 (32.7) 0.009
Statin use at follow up coronary CTA 107 (72.8) 37 (100) 70 (63.6) <0.001
Laboratory test before index coronary CTA
T-chol, mg/dl 183  35 177  38 185  32 0.242
HDL-C, mg/dl 48  10 48  9 48  11 0.959
LDL-C, mg/dl 114  35 106  37 116  32 0.125
TG, mg/dl 154  8.2 150  69 157  88 0.689
Statin use 57 (38.8) 21 (56.8) 36 (32.7) 0.009
Laboratory test at follow up coronary CTA
T-chol, mg/dl 162  37 126  15 176  34 <0.001
HDL-C, mg/dl 48  11 48  12 47  10 0.832
LDL-C, mg/dl 92  32 57  12 104  27 <0.001
TG, mg/dl 122  72 104  52 126  76 0.105
Values are n (%) or mean  SD.
HDL-C ¼ high-density lipoprotein cholesterol; T-chol ¼ total cholesterol; TG ¼ triglyceride; other
abbreviations as in Tables 1 and 2.
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441showed a signiﬁcant relationship in previous studies
and parameters with a p value <0.3 in the univariate
analysis were deﬁned as confounding variables
related to the dependent and independent measures.
The latter covariates included age, hypertension,
active smoking, and follow-up LDL-C <70 mg/dl. All
statistical analyses were performed using the Statis-
tical Package for the Social Sciences version 19 (SPSS,
Chicago, Illinois), and a p value <0.05 was considered
signiﬁcant for all analyses.
RESULTS
STUDY POPULATION. Clinical characteristics of the
patients are reported in Table 2. The mean age was
62  8 years, and 57% of the patients were male.
Hypertension, diabetes mellitus, and dyslipidemia
were present in 65%, 33%, and 47% of the patients,
respectively. In addition, 20% of the patients were
active smokers. Patients exhibiting a follow-up
LDL-C <70 mg/dl had a higher prevalence of dia-
betes mellitus (p ¼ 0.002). Although, there was no
difference in National Cholesterol Education Program
Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment
Panel III) (NCEP ATP III) score and Framingham risk
scores between the 2 groups, the number of risk
factors were greater in the follow-up LDL <70 mg/dl
group (1.95  1.08 vs. 1.54  0.95; p ¼ 0.029). During
a mean interscan period of 3.2  1.1 years, use of
statins increased considerably after baseline coronary
CTA imaging (38.8% vs. 72.8%; p < 0.001), with a
higher rate of use in patients achieving follow-up
LDL-C <70 mg/dl (Table 3, Figure 3).
COMPARISON BETWEEN BASELINE AND FOLLOW-
UP CHANGES IN CORONARY ARTERIES AND
ATHEROSCLEROSIS PROGRESSION. Changes in cor-
onary artery severity and atherosclerotic progression
between baseline and follow-up study are displayed
in Table 4. During this time, the lumen volume
decreased (p < 0.001), whereas the vessel volume
(p ¼ 0.029), plaque volume (p < 0.001), and the pro-
portion of dense calciﬁed plaque (p < 0.001)
increased. Furthermore, signiﬁcant elevation in mean
plaque burden (p < 0.001) and plaque burden at the
minimal lumen area (p < 0.001) were also observed.
Total plaque volume change was 36.3  67.7 mm3, and
the annual change in plaque volume was 13.0  25.1
mm3 based on a per-patient analysis. The mean
annual plaque volume progression rate was 3.63 
5.83% (Figure 4).
CORONARY ARTERY AND ATHEROSCLEROSIS CHANGES
AS A FUNCTION OF LDL-C CONTROL. Patients
achieving a LDL-C <70 mg/dl demonstrated a lowerprogression in plaque volume compared with patients
with follow-up LDL-C levels $70 mg/dl (p ¼ 0.014).
Likewise, the annual change in plaque volume was
also attenuated for patients achieving low LDL-C <70
mg/dl levels (p ¼ 0.018) (Figure 5). Factors associated
with annual plaque progression in the univariate
analysis were age, body mass index (BMI), hyper-
tension, and follow-up LDL-C level $70 mg/dl.
TABLE 4 Change in
Lesion length, mm
Vessel volume, mm3
Lumen volume, mm3
Plaque volume, mm3
Dense calcium, mm3
Proportion of dense ca
Mean plaque burden, %
Maximal plaque thickn
Minimal lumen area, m
Minimal lumen diamete
Plaque burden at minim
Values are median (interqu
LAD ¼ left anterior desc
artery.
FIGURE 3 The Change of Statin Use After Index Coronary CTA
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Use of statins increased considerably after baseline coronary computed tomography
angiography (CTA) imaging. Fifty patients newly initiated using statin, and 15 patients
increased the dose of statin.
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442In per-patient multivariate analysis, follow-up LDL-C
levels $70 mg/dl (beta 0.193; p ¼ 0.021) were strong
determinants of annual plaque progression adjusted
by age, BMI, hypertension, and active smoking
(Table 5). However, when the baseline plaque volume
was adjusted, the plaque volume was veriﬁed as a
signiﬁcant factor (beta 0.324; p < 0.001), and the
follow-up LDL $70 mg/dl was found not to be sig-
niﬁcant, but rather only showed a trend (beta 0.158;
p ¼ 0.059). Additionally, according to the per-vessel
analysis, age, BMI, active smoking, and follow-up
LDL-C $70 mg/dl were determinant factors for
annual plaque progression (Online Tables 1, 2).Lesion Characteristics Between Initial and Follow-Up Coronary CTA
Initial
(N ¼ 336)
Follow Up
(N ¼ 336) p Value
17.0 (10.1–25.8) 17.0 (10.1–25.8) 0.486
220.8 (124.0–377.5) 223.2 (130.7–379.4) 0.616
105.9 (63.4–197.5) 97.9 (58.1–170.1) <0.001
114.3 (63.8–200.3) 118.7 (69.1–221.6) <0.001
10.8 (3.1–33.7) 24.4 (9.8–60.6) <0.001
lcium, % 10.0 (3.3–22.6) 22.3 (11.9–33.9) <0.001
51.7 (44.2–57.7) 55.1 (48.9–60.9) <0.001
ess, mm 1.73 (1.37–2.12) 1.85 (1.59–2.28) <0.001
m2 5.0 (3.7–6.9) 4.5 (3.2–6.1) <0.001
r, mm 2.3 (1.9–2.7) 2.1 (1.7–2.5) <0.001
al lumen area, % 61.4 (52.4–70.5) 66.6 (59.9–74.4) <0.001
artile range).
ending coronary artery; LCX ¼ left circumﬂex coronary artery; RCA ¼ right coronarySUBGROUP ANALYSIS COMPARING STATIN USERS
WHO ACHIEVED LDL-C <70 mg/dl VERSUS THOSE
WHO DID NOT. A subgroup analysis on all statin users
(n ¼ 107), to see whether a more aggressive LDL-C
approach could reduce plaque progression, was per-
formed. All patients achieving a LDL-C<70 mg/dl took
statin (n ¼ 37), whereas 63% (n ¼ 70) patients with
follow-up LDL-C levels $70 mg/dl were on statin.
Subgroup analysis of patients taking statins demon-
strate that the annual plaque volume progression (4.6
 15.0 mm3 vs. 14.5  22.0 mm3; p ¼ 0.015) could be
attenuated with aggressive LDL control (Table 6).
DISCUSSION
The present study demonstrated that achievement of
LDL-C control to levels <70 mg/dl is associated with a
reduced rate and volume of plaque progression, both
on a per-patient as well as per-vessel basis. Further,
we observed that per-patient annual plaque volume
increased in this near-term period on the basis of
presence of age and active smoking, but not by the
presence of diabetes mellitus or hypertension.
Conventionally, quantitative coronary angiography
or IVUS have been employed for diagnosis of coronary
atherosclerosis or coronary artery stenosis. However,
a potential pitfall of these procedures is their rela-
tively expensive cost as well as their inherent
invasive nature (21,22). Recent improvements in CT
technology have permitted characterization of plaque
morphology (23,24), quantiﬁcation of plaque volume
(25,26), and stenosis evaluation (12,27). There have
been numerous attempts to utilize coronary CTA for
measuring plaque volume and to reveal other clinical
implications, such as use for estimating ischemia (28).
However, these attempts have been performed
manually, examining 1-mm cross-sectional slices of
the coronary vascular bed, requiring considerable
time and effort, and making large-scale investigations
difﬁcult. Hence, most research involving plaque vol-
ume assessments by coronary CTA have examined
only a small number of patients. Recently developed
semiautomated plaque quantiﬁcation methods allow
for the measurement of plaque volumes with only
minor modiﬁcations, thereby increasing the speed of
assessment and allowing more patients to be enrolled
in these studies. Coronary CTA utilizing these semi-
automated techniques is highly reproducible (29),
with plaque volumes correlating well with plaque
volumes measured by IVUS (19,30). Coronary CTA has
several advantages over IVUS, given its noninvasive
nature, as well as overall cost. Therefore, coronary
CTA may prove useful for future quantitative research
into plaque progression.
FIGURE 4 Changes in Coronary Artery and Atherosclerotic Progression Between Baseline and Follow-Up Periods
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Median 2.29 [0.12-6.02] %
Total plaque volume change was 36.3  67.7 mm3 (A) and the mean annual plaque progression rate was 3.63  5.83% (B). LDL-C ¼ low-
density lipoprotein cholesterol.
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443LDL-C contributes to the progression of athero-
sclerotic CAD. Furthermore, numerous serial IVUS
studies have demonstrated that strict LDL-C control
can lead to plaque retardation or regression, as well asFIGURE 5 Coronary Artery and Atherosclerosis Changes as a Functi
Change in
Plaque Volume
Annual Change in
Plaque Volume
60
50
40
30
20
10
0
-10
Follow Up LDL-C Follow Up LDL-C
Ch
an
ge
 o
f P
la
qu
e 
Vo
lu
m
e 
(m
m3
)
Ch
an
ge
 o
f P
la
qu
e 
Vo
lu
m
e 
(m
m3
)
30
20
10
0
-10
p = 0.014 p = 0.018 60
40
30
20
10
0
-60
BA
Fr
eq
ue
nc
y 
(n
)
≥ 70 mg/dl< 70 mg/dl
Patients achieving a low-density lipoprotein cholesterol (LDL-C) <70 m
with patients with follow-up LDL-C levels $70 mg/dl (A). Likewise, the
achieving low LDL-C <70 mg/dl level (the mean interscan period was 3prior research studies incorporating CT. In the
ASTEROID (A Study To Evaluate the Effect of Rosu-
vastatin on Intravascular Ultrasound-Derived Coro-
nary Atheroma Burden) trial (7), patients using veryon of LDL-C Control
-30 0 30 60 90 120 150 180
The Change of Annual Plaque Volume (mm3)
Follow up LDL ≥ 70 mg/dlFollow up LDL < 70 mg/dl
g/dl demonstrated a lower progression in plaque volume compared
annual change in plaque volume was also attenuated for patients
.2  1.1 years) (A and B).
TABLE 5 Association Between Annual Plaque Volume Change and
Clinical Variables
Univariate
Beta p Value
Multivariate
Beta p Value
Age, yrs 0.130 0.118 0.149 0.077
Male 0.083 0.316
BMI, kg/m2 0.165 0.045 0.113 0.178
Hypertension 0.170 0.040 0.143 0.089
Diabetes mellitus 0.039 0.639
Active smoking 0.105 0.207 0.125 0.137
Follow-up LDL-C $70 mg/dl 0.195 0.018 0.193 0.021
Statin use 0.123 0.137
The mean interscan period was 3.2  1.1 years.
Abbreviations as in Table 1.
TABLE 6 Subgroup A
Initial plaque volume, m
Change in plaque volum
Annual change in plaqu
Values are mean  SD.
Abbreviations as in Tabl
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444high-intensity statin therapy achieved an average
LDL-C of 60.8 mg/dl and demonstrated signiﬁcant
atherosclerosis regression. Similarly, Inoue et al. (18)
enrolled 32 patients, with 24 individuals receiving
ﬂuvastatin treatment. These patients underwent se-
rial coronary CTA imaging after a median treatment
interval of 12 months. The study conﬁrmed that pla-
que volume, especially low-attenuation plaque vol-
ume, was reduced. However, low-dose statin (10 mg)
over this short period did not mediate changes in the
total plaque volume. Moreover, the study omitted
patients with severe calciﬁcation, thus introducing
potential selection bias that may have inﬂuenced the
general applicability of these ﬁndings. Recently,
another serial coronary CTA study reported that
statin therapy resulted in a reduced low-attenuation
plaque progression compared to that observed in
non-statin users (31). The present study’s ﬁndings are
in line with these prior studies and extend the overall
literature that demonstrates the potential utility of
coronary CTA, not only for clinical evaluation of
atherosclerosis progression, but also for examining
volumetric differences in atherosclerotic plaques
over time. To our knowledge, these data represent
the longest interscan period for a serial study to date,
and provide information as to the longitudinal effects
of therapy on atherosclerosis.nalysis of Patients Taking Statins
F/U LDL-C
<70 mg/dl
(n ¼ 37)
F/U LDL-C
$70 mg/dl
(n ¼ 70) p Value
m3 274  193 359  295 0.118
e, mm3 12.7  38.2 41.8  60.0 0.009
e volume, mm3 4.6  15.0 14.5  22.0 0.015
e 3.The ACC/AHA guidelines (32), published in 2013,
recommended basing the decision on scoring system
and that patients whose overall 10-year risk score was
determined to be 7.5% or greater should start statin
therapy. In these guidelines, a “treat to target” goal
for LDL-C is no longer recommended. However, our
subgroup analysis showed that even though the
patients used statin, reducing LDL-C lower than
70 mg/dl attenuated plaque progression, which
means using statin is not always effective to reduce
plaque progression.
Given the strong relationship between LDL-C
lowering and reduction of atherosclerosis progres-
sion, the present ﬁndings indicate that noninvasive
evaluation of plaque volumetric changes can be used
as a surrogate marker of cardiovascular risk. Assess-
ment of morbidity and mortality as primary end-
points in conventional large-scale clinical trials of
established and novel agents is and will remain the
“gold standard” assessment of therapeutic efﬁcacy.
Nevertheless, these studies are generally hindered by
a considerable ﬁnancial cost and lengthy follow-up
duration. Invasive imaging has therefore been
employed to evaluate atherosclerosis as a surrogate
marker in clinical trials that are designed to investi-
gate plaque progression. Given the safety concerns,
patients enrolled in invasive imaging studies (pri-
marily IVUS) have been selected as a function of the
disease burden, with prior investigations requiring
individuals to have one obstructed vessel and another
diseased coronary vessel that has not undergone an-
gioplasty. Therefore, only patients with advanced
atherosclerotic, obstructive disease have traditionally
been enrolled in IVUS studies. IVUS studies remain
expensive and invasive, and are inappropriate for
routine serial follow-up studies. By contrast, we were
able to evaluate patients with mild and moderate
plaque burden in our current study, based on the
noninvasive nature of coronary CTA, which permits
plaque quantiﬁcation with accuracy similar to IVUS
(19). However, a randomized prospective comparative
trial between coronary CTA and IVUS will be needed.
STUDY LIMITATIONS. This was a retrospective study,
which might have potentially led to selection bias.
Furthermore, only baseline and ﬁnal lipid data were
available, and as a consequence, longitudinal LDL-C
control between coronary CTAs could not be
conﬁrmed. The fact that the proportion of patients on
statin during the follow-up period was higher in the
LDL <70 mg/dl group was a predictable result, indi-
cating the individual clinician felt the risk to be high
enough in the LDL <70 mg/dl group to set up a low
target for control. However, the lack of signiﬁcant
correlation between statin administration and plaque
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This study
explores the relationship between temporal changes in coronary
plaque volume and the intensity of lipid-lowering treatments by
serial coronary CTA. Among the patients with CAD according to
coronary CTA, achievement of LDL-C control to levels <70 mg/dl
decreased the progression of annual plaque volumes as observed
by serial coronary CTA. Furthermore, subgroup analysis of
patients taking statins also demonstrated that the annual plaque
volume progression could be attenuated with aggressive LDL
control.
TRANSLATIONAL OUTLOOK: This study provides signiﬁcant
evidence that coronary plaque volume can be decreased by strict
LDL-C control and also shows the possibility of quantitating
plaque progression on the basis of serial coronary CTA. Addi-
tional studies are required to conﬁrm that the noninvasive cor-
onary CTA may be used as a useful tool for quantitative analysis
of response to medications in the future.
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445progression (Table 5) could be secondary to the
fact that statin usage at a given time point was
denoted to represent the entire follow-up period,
which is a limitation of this retrospective study.
When the baseline plaque volume was adjusted, the
plaque volume was veriﬁed as a signiﬁcant factor,
and this attenuates the impact of follow-up LDL
$70 mg/dl level, but rather only showed a trend.
Therefore, it is correct that larger plaque volume at
baseline leads to larger increase in plaque volume.
However, there was no signiﬁcant difference in the
baseline plaque volume between the 2 groups, and
lower LDL level, which is a modiﬁable factor, can
markedly inﬂuence plaque progression in addition to
the baseline plaque volume. Although we employed
strict, standardized criteria for coronary CTA assess-
ment, atherosclerosis ﬁndings may be inﬂuenced by
the Hounsﬁeld unit density, which is affected by a
myriad of factors. Hence, decisions regarding plaque,
lumen, or vessel volumes in this study were based on
consensus among at least 2 physicians viewing the
same data. Despite these limitations, this study used
coronary CTA to estimate plaque volume in multiple
patients and conﬁrmed that plaque progression was
slowed in patients who strictly controlled their LDL-C
levels.
CONCLUSIONS
The present study demonstrated that achievement of
LDL-C control to levels <70 mg/dl are associated with
a reduced rate and volume of plaque progression.Therefore, strict LDL-C control results in a decrease
in the progression of annual plaque volumes as
observed by serial coronary CTA.
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